Retractable Technologies posts $7.2 million in Q2 sales as EasyPoint demand softens
Medical device procurement in the safety-needle segment shifted in the second quarter, driven by a return to seasonal buying norms after an atypical flu-season rush in 2025. Retractable Technologies (NYSE American: RVP) reported…
Key takeaways
- Retractable Technologies reported $7.2 million in net sales for the quarter ended June 30, 2026, down from $10.4 million a year earlier.
- The company posted a $5.1 million operating loss but net income of $2.8 million, driven by a one-time $6.4 million realized gain on the sale of equity securities.
- Overall unit sales fell 36.4%, which management attributed to flu-season EasyPoint needle orders being pulled forward into Q2 2025, with the bulk of 2026 flu-season volume expected in Q3.
- Domestic revenues fell 30.8% and international revenues fell 32.2%, primarily due to lower EasyPoint needle sales.
- For the first six months of 2026, net sales were $14.4 million versus $18.7 million a year earlier, with the operating loss widening to $11.3 million from $9.8 million.
Medical device procurement in the safety-needle segment shifted in the second quarter, driven by a return to seasonal buying norms after an atypical flu-season rush in 2025. Retractable Technologies (NYSE American: RVP) reported $7.2 million in net sales for the three months ended June 30, 2026, down from $10.4 million in the same period a year earlier, with an operating loss of $5.1 million that matched the prior-year figure exactly.
What moved the numbers
The year-over-year revenue decline was shaped less by structural demand loss and more by timing. Management said purchasing patterns in the second quarter of 2025 were unusually concentrated, pulling flu-season EasyPoint needle orders forward into that period. The 2026 quarter reverted to a more traditional cadence, with the bulk of flu-season volume expected in Q3. That explanation accounts for much of the 36.4% drop in overall unit sales reported for the period.
In a softer demand environment, both domestic and international channels felt the pressure. Domestic revenues fell 30.8%, international revenues fell 32.2%. The primary driver in both cases was a decrease in EasyPoint needle sales. International orders carry lower average selling prices than domestic ones, and Retractable noted continued uncertainty around the timing of future cross-border orders. Products reach customers through specialty and general line distributors, and order timing from those buyers added to the volatility in the quarterly comparison.
Tariffs, sourcing, and a one-time gain
Against the backdrop of a tightened tariff environment, the company spent approximately $46 thousand on tariff costs in Q2 2026, a reduction from prior periods. Mitigation efforts included strategic sourcing shifts and an increase in domestic manufacturing. Domestic production reached 42.4% of units made in the first half of 2026, up from 38% in the first half of 2025. The filing cautioned that tariffs may continue to materially affect costs in future periods.
The bottom line was rescued by a one-time event: a $6.4 million realized gain on the sale of equity securities pushed net income to $2.8 million for the quarter, even as operations ran at a $5.1 million loss. A reduction in force carried out in April 2026 is expected to generate savings in future periods, according to the filing, though no specific figure was attached to that projection. For the first six months of 2026, net sales totaled $14.4 million against $18.7 million in the prior year, with the six-month operating loss widening to $11.3 million from $9.8 million, driven by lower revenue and increased operating expenses the company attributed primarily to donation expense.
On balance, the macro caveat is tariff exposure and the still-uncertain timing of international orders. Retractable's own filing puts the majority of flu-season sales in Q3, and that is the quarter that will test whether the timing explanation holds.
Related reading
Source · 來源